Literature DB >> 23130989

In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.

Ana P M Teston1, Wuelton M Monteiro, Daniele Reis, Gleison D P Bossolani, Mônica L Gomes, Silvana M de Araújo, Maria T Bahia, Maria G V Barbosa, Max J O Toledo.   

Abstract

OBJECTIVE: To assess the susceptibility of Trypanosoma cruzi strains from Amazon to benznidazole.
METHODS: We studied 23 strains of T. cruzi obtained from humans in the acute phase of Chagas disease, triatomines and marsupials in the state of Amazonas and from chronic patients and triatomines in the state of Paraná, Brazil. The strains were classified as TcI (6), TcII (4) and TcIV (13). For each strain, 20 Swiss mice were inoculated: 10 were treated orally with benznidazole 100 mg/kg/day (TBZ group) for 20 consecutive days and 10 comprised the untreated control group (NT). Fresh blood examination, haemoculture (HC), PCR, and ELISA were used to monitor the cure.
RESULTS: The overall cure rate was 60.5% (109/180 mice) and varied widely among strains. The strains were classified as resistant, partially resistant or susceptible to benznidazole, irrespective of discrete typing units (DTUs), geographical origin or host. However, the TcI strains from Amazonas were significantly (P = 0.028) more sensitive to benznidazole than the TcI strains from Paraná. The number of parasitological, molecular and serological parameters that were significantly reduced by benznidazole treatment also varied among the DTUs; the TBZ group of mice inoculated with TcIV strains showed more reductions (8/9) than those with TcI and TcII strains.
CONCLUSIONS: Benznidazole resistance was observed among natural populations of the parasite in the Amazon, even in those never exposed to the drug.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23130989     DOI: 10.1111/tmi.12014

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  25 in total

1.  Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Authors:  Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

Review 2.  Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease.

Authors:  Louisa A Messenger; Michael A Miles; Caryn Bern
Journal:  Expert Rev Anti Infect Ther       Date:  2015-08       Impact factor: 5.091

Review 3.  Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.

Authors:  Christian Olivo Freites; Hendrik Sy; Amal Gharamti; Nelson I Agudelo Higuita; Carlos Franco-Paredes; José Antonio Suárez; Andrés F Henao-Martínez
Journal:  Curr Heart Fail Rep       Date:  2022-08-11

4.  Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.

Authors:  Silvane Maria Fonseca Murta; Laila Alves Nahum; Jéssica Hickson; Lucas Felipe Almeida Athayde; Thainá Godinho Miranda; Policarpo Ademar Sales Junior; Anderson Coqueiro Dos Santos; Lúcia Maria da Cunha Galvão; Antônia Cláudia Jácome da Câmara; Daniella Castanheira Bartholomeu; Rita de Cássia Moreira de Souza
Journal:  Parasit Vectors       Date:  2022-06-06       Impact factor: 4.047

5.  Infection susceptibility and vector competence of Rhodnius robustus Larrousse, 1927 and R. pictipes Stal, 1872 (Hemiptera, Reduviidae, Triatominae) for strains of Trypanosoma cruzi (Chagas, 1909) (Kinetoplastida, Trypanosomatidae) I, II and IV.

Authors:  Ana Paula de Abreu; Hevillyn Fernanda Lucas da Silva; Marcella Paula Mansano Sarto; Giullia Ferreira Iunklaus; João Vitor Trovo; Nilma de Souza Fernandes; Ana Paula Margioto Teston; Max Jean de Ornelas Toledo
Journal:  Parasit Vectors       Date:  2022-06-30       Impact factor: 4.047

6.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Authors:  Juan M Bustamante; Julie M Craft; Byron D Crowe; Sarah A Ketchie; Rick L Tarleton
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

7.  Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells.

Authors:  Robson Xavier Faria; Daniel Tadeu Gomes Gonzaga; Paulo Anastácio Furtado Pacheco; André Luis Almeida Souza; Vitor Francisco Ferreira; Fernando de Carvalho da Silva
Journal:  J Bioenerg Biomembr       Date:  2018-02-23       Impact factor: 2.945

8.  A Combination of Itraconazole and Amiodarone Is Highly Effective against Trypanosoma cruzi Infection of Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Roy T Madigan; Lydia-Marie Joubert; Adriana Bozzi; Nazish Sayed; Joseph C Wu; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 9.  Translational challenges of animal models in Chagas disease drug development: a review.

Authors:  Eric Chatelain; Nandini Konar
Journal:  Drug Des Devel Ther       Date:  2015-08-19       Impact factor: 4.162

10.  Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.

Authors:  Carolina B Moraes; Miriam A Giardini; Hwayoung Kim; Caio H Franco; Adalberto M Araujo-Junior; Sergio Schenkman; Eric Chatelain; Lucio H Freitas-Junior
Journal:  Sci Rep       Date:  2014-04-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.